Xencor Inc

NASDAQ:XNCR   3:59:50 PM EDT
35.52
+0.99 (+2.87%)
Earnings Announcements

Xencor Reports Third Quarter 2021 Financial Results And Announces Encouraging Preliminary Data From Ongoing Phase 1 Study Of Potency-Reduced Il15-FC Cytokine, Xmab306

Published: 11/08/2021 21:12 GMT
Xencor Inc (XNCR) - Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data From Ongoing Phase 1 Study of Potency-reduced Il15-fc Cytokine, Xmab306.
Q3 Loss per Share $0.69.
Q3 Revenue $19.7 Million.
Q3 Earnings per Share View $-0.65, Revenue View $19.0 Million -- Refinitiv Ibes Data (analyst estimates).
Exceptional Nk Cell Expansion of 40- to 100-fold Increases Compared to Baseline, With Good Tolerability to Date, Has Been Observed.
Revenue is expected to be $18.92 Million
Adjusted EPS is expected to be -$0.72

Next Quarter Revenue Guidance is expected to be $26.03 Million
Next Quarter EPS Guidance is expected to be -$0.65

More details on our Analysts Page.